Attenuated Coronavirus Preparations for Mitochondrial Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines and treatments for coronaviruses, such as SARS-CoV and SARS-CoV2, are limited by production constraints, distribution challenges, and lack an effective method to modulate mitochondrial function, which is crucial for viral replication and host immune response.
Innovation Solution
Development of attenuated, engineered coronavirus strains that can replicate and spread, specifically by silencing or deleting genes affecting mitochondrial function, such as ORF 9b and ORF 10, to create a safer and more effective treatment, vaccine, or antidote.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If current vaccines and treatments are used, then production and distribution can be constrained, but accessibility and availability in developing countries deteriorate
Solution Approach 1:
The patent extracts the essential immunogenic components (mitochondrial-targeting peptides and viral antigens) from complex vaccine formulations, creating a simplified treatment composition that can be produced and distributed more easily while maintaining therapeutic effectiveness against coronavirus infections
Solution Approach 2:
The patent uses engineered attenuated coronavirus strains that replicate and spread to create immune response, essentially copying the natural infection process in a controlled manner to provide immunity without the full pathogenicity of wild-type viruses
2Productivity
If wild-type coronavirus is used for treatment, then viral replication capability is maintained, but safety and mitochondrial interference worsen
Solution Approach 1:
The patent removes or attenuates specific genes (such as ORF9b and other mitochondrial-targeting genes) from the coronavirus genome, extracting the harmful mitochondrial interference capability while preserving the virus's ability to replicate and induce immune response
Solution Approach 2:
The patent creates viruses with localized modifications where only specific genes affecting mitochondrial function are altered, leaving the rest of the viral genome intact to maintain replication capability and immunogenicity
3Object-affected harmful factors
If gene silencing is applied to reduce mitochondrial interference, then safety improves, but viral replication capability may deteriorate
Solution Approach 1:
The patent applies partial gene silencing or attenuation, reducing but not completely eliminating mitochondrial interference, which allows the virus to maintain sufficient replication capability for effective treatment while significantly reducing harmful effects on host mitochondria
Data Source
AI summary
Attenuate coronavirus species that are able to fully replicate and spread are proposed together with the methods of obtaining thereof. The proposed coronavirus species are intended to treat and prevent viral infections including all those caused by coronavirus species that affect humans as the COVID-19 caused by the SARS-CoV2. Compared with other treatment or vaccine alternatives, the availability of such attenuate coronavirus species does not require of significant distribution and production resources. Some of the embodiments of the invention involve the use of the attenuate coronavirus species in formulations or compositions that have to be approved as safe and effective for therapeutic use in specific territories by a valid regulatory agency as the Food and Drug Agency (FDA) in the United States.